<unk>  and<unk>  beta each work by binding to GD2, a glycolipid found on cells originating from the neuroectoderm during prenatal development, including neurons in the central nervous system and in the peripheral nervous system. Neuroblastoma cells have this as well. When<unk>  binds to any cell that has GD2, that cell is destroyed via cell-mediated cytotoxicity and complement-dependent cytotoxicity. In clinical trials of<unk> , the maximum plasma concentration was 11.5 mcg/mL; the mean steady state volume distribution was 5.4 L; the clearance rate was 0.21 L/day; and the average half-life was 10 days.
Dinutuximab
Siltuximab
Margetuximab
Isatuximab
Loncastuximab tesirine
Blinatumomab
Polatuzumab vedotin
Tucatinib